ArticleAnnals of neurology2026
Monitoring Antiseizure Medication Change Using Ultra Long-Term Electroencephalogram: A Multicenter Study.
Article in Annals of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is Ultra-Long-Term Subscalp EEG Ready to Go "Solo"? Transforming the Landscape of Antiseizure Medication Management.Epilepsy currents · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
objectiveMedication dose adjustments are common in treatment-resistant epilepsy, but lack robust evidence, and patient-reported seizure diaries have known limitations. We assessed whether ultra long-term subcutaneous electroencephalogram (sqEEG) improves detection of seizure frequency changes after antiseizure medication adjustments.
methodsA retrospective, multicenter cohort study was carried out across 9 centers in adults with treatment-resistant epilepsy. SqEEG seizure frequency was compared with seizure diaries before and after medication dose increases and reductions, over 7-, 14-, and 30-day windows, using categorical analyses, mixed-effects models and survival analyses.
resultsA total of 65 participants (mean age 40.6 years; 59% female) contributed >280,000 hours of sqEEG, 9,190 electrographic seizures and 4,850 diary events, including across 160 medication changes. Categorical disagreement between modalities ranged from 36% to 50%, with significant differences at 7 and 14 days for dose reductions, and at 14 days for dose increases. sqEEG recorded 2.2- to 3.4-fold more seizures than diary across all seizure count models (all p < 0.01). Seizure count models showed no statistically significant difference between modalities in detecting treatment-related changes (interaction estimates: 5-38% larger increases with sqEEG for dose reductions, and 13-38% larger reductions with sqEEG for dose increases). SqEEG identified return to baseline seizure counts significantly earlier than diary after dose reductions at 7- and 14-day windows (median 7 vs 13 days and 10 vs 17 days, respectively; adjusted p = 0.046 and 0.042).
interpretationSqEEG detects more seizures than patient-reported diaries and identifies treatment-related changes earlier, even after modest medication adjustments, particularly after dose reductions, highlighting the potential of objective ultra long-term EEG monitoring in treatment-resistant epilepsy. ANN NEUROL 2026;100:600-612.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.